Holen Sie sich die Stockscreener-App
9.40
0.00%
0.00
Handel nachbörslich:
11.41
2.01
+21.38%
Schlusskurs vom Vortag:
$9.40
Offen:
$9.34
24-Stunden-Volumen:
267.96K
Relative Volume:
1.57
Marktkapitalisierung:
$310.97M
Einnahmen:
$65.42M
Nettoeinkommen (Verlust:
$-32.96M
KGV:
-7.4016
EPS:
-1.27
Netto-Cashflow:
$-19.87M
1W Leistung:
-11.49%
1M Leistung:
-13.92%
6M Leistung:
-21.54%
1J Leistung:
+47.57%
1-Tages-Spanne:
$9.23
$9.555
1-Wochen-Bereich:
$9.22
$10.80
52-Wochen-Spanne:
$6.27
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Vergleichen Sie NPCE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
9.40 | 310.97M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
125.80 | 215.34B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.84 | 146.15B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
362.61 | 136.97B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
90.42 | 115.69B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
84.15 | 48.77B | 5.88B | 1.34B | 577.90M | 2.3455 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
NeuroPace Reports Record Revenue and Raises Guidance - TipRanks
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance - BioSpace
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: NeuroPace Q3 2025 beats EPS, raises guidance - Investing.com
NeuroPace Inc.: Q3 Earnings Snapshot - San Francisco Chronicle
NeuroPace reports Q3 EPS (11c), consensus (19c) - TipRanks
[10-Q] NeuroPace Inc Quarterly Earnings Report | NPCE SEC FilingForm 10-Q - Stock Titan
NeuroPace's Q3 revenue beats estimates - MarketScreener
[8-K] NeuroPace Inc Reports Material Event | NPCE SEC FilingForm 8-K - Stock Titan
What technical models suggest about NeuroPace Inc.’s comeback2025 Big Picture & High Return Trade Opportunity Guides - newser.com
Published on: 2025-11-04 02:38:39 - newser.com
Applying Elliott Wave Theory to NeuroPace Inc.2025 Market Outlook & Safe Capital Growth Tips - newser.com
Evaluating NeuroPace Inc. with trendline analysisTrade Analysis Summary & Weekly Market Pulse Updates - newser.com
NeuroPace, Inc. (NPCE) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
NeuroPace, Inc. (NPCE) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Neuropace, Inc. Advances in Treating Lennox-Gastaut Syndrome: A Study Update - MSN
Real time alert setup for NeuroPace Inc. performance2025 Institutional Moves & Weekly Setup with High ROI Potential - newser.com
Using RSI to spot recovery in NeuroPace Inc.Bull Run & Low Drawdown Investment Ideas - newser.com
Why NeuroPace Inc. stock is a value investor pickSwing Trade & Safe Investment Capital Preservation Plans - newser.com
Will NeuroPace Inc. stock gain from government policies2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - newser.com
How to escape a deep drawdown in NeuroPace Inc.Earnings Recap Summary & Daily Stock Momentum Reports - newser.com
NeuroPace Inc (NPCE) Q3 2025 Earnings Report Preview: What to Look For - Yahoo Finance
Can momentum traders help lift NeuroPace Inc.Trade Volume Summary & Advanced Technical Analysis Signals - newser.com
Using data tools to time your NeuroPace Inc. exitJuly 2025 Final Week & Real-Time Stock Price Movement Reports - newser.com
What technical signals suggest for NeuroPace Inc. stockMarket Sentiment Report & AI Based Trade Execution Alerts - newser.com
What is the fair value of NeuroPace Inc. stock now2025 Short Interest & Comprehensive Market Scan Insights - newser.com
Will NeuroPace Inc. price bounce be sustainableMarket Risk Report & AI Enhanced Execution Alerts - newser.com
Why NeuroPace Inc. stock is seen as undervaluedWeekly Investment Summary & Fast Exit and Entry Trade Guides - newser.com
Can NeuroPace Inc. stock sustain revenue growthJuly 2025 Gainers & Weekly Sector Rotation Insights - newser.com
Will NeuroPace Inc. stock recover faster than marketJuly 2025 Recap & Expert Approved Momentum Trade Ideas - newser.com
Tools to assess NeuroPace Inc.’s risk profilePortfolio Performance Report & Consistent Profit Focused Trading Strategies - newser.com
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Operating expenses (excl. COGS) of Neuropace, Inc. – BOATS:NPCE - TradingView
Can NeuroPace Inc. stock resist market sell offsTrade Volume Summary & AI Enhanced Trading Alerts - newser.com
NeuroPace Inc. stock outlook for YEARTrade Volume Summary & High Win Rate Trade Alerts - newser.com
Can NeuroPace Inc. stock withstand economic slowdown2025 Valuation Update & High Yield Stock Recommendations - newser.com
Does NeuroPace Inc. fit your quant trading modelJuly 2025 Institutional & Real-Time Stock Movement Alerts - newser.com
Neuropace Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Neuropace, Inc. (NPCE) Stock forecasts - Yahoo! Finance UK
Strategies to average down on NeuroPace Inc.Portfolio Profit Report & Smart Allocation Stock Tips - newser.com
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):